Drug Combination Details
General Information of the Combination (ID: C18595) | |||||
---|---|---|---|---|---|
Name | Apigenin NP Info | + | Sorafenib Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP10 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN2A | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combination of apigenin and sorafenib arrested cell cycle and increased apoptotic gene expressions more than single treatment groups. |
References | ||||
---|---|---|---|---|
Reference 1 | Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene. 2020 May 5;737:144428. |
![](/sites/default/files/kegg_pathway/hsa04210+637.png)
![](/sites/default/files/kegg_pathway/hsa04210+843.png)
![](/sites/default/files/kegg_pathway/hsa04210+836.png)
![](/sites/default/files/kegg_pathway/hsa04210+841.png)
![](/sites/default/files/kegg_pathway/hsa04110+1026.png)
![](/sites/default/files/kegg_pathway/hsa04110+1029.png)